<DOC>
	<DOCNO>NCT00002687</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-2 treating patient mycosis fungoides .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Mycosis Fungoides</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose toxicity interleukin-2 patient stage IIB-IV mycosis fungoides . - Determine response rate patient treat regimen . - Determine immunologic response regimen peripheral blood leukocyte serum patient . OUTLINE : This dose escalation study . Patients receive interleukin-2 ( IL-2 ) subcutaneously day 1-5 week 1-3 day 1-3 5 week 4 . Treatment repeat every 4 week 4 course . Cohorts 3-6 patient receive escalate dos IL-2 maximum tolerate dose ( MTD ) determine . The MTD define dose 3 6 patient experience dose-limiting toxicity . Six additional patient receive IL-2 1 dose level precede MTD . Patients follow least 3 time year 1 annually thereafter . PROJECTED ACCRUAL : A total 16-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinically histologically proven diagnosis 1 following : Mycosis fungoides ( MF ) meet 1 follow condition : Stage IIB disease fail psoralen ultraviolet A ( PUVA ) light therapy topical chemotherapy ( mechlorethamine and/or carmustine ) Stage III disease generalize erythroderma Stage IV disease biopsy proven nodal visceral involvement Sezary syndrome Stage III MF minimum 20 % Sezary cell ( base total WBC ) No clinically significant ascites pleural effusion Clinically significant pleural effusion define shortness breath oxygen saturation le 90 % PATIENT CHARACTERISTICS : Age : 18 80 Performance status : Karnofsky 70100 % Life expectancy : At least 16 week Hematopoietic : See Disease Characteristics WBC least 3,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 11.5 g/dL Hepatic : Bilirubin le 2.5 time normal SGOT le 2.5 time normal Renal : Creatinine great 2.0 mg/dL No nephrotic syndrome Cardiovascular : No history myocardial infarction congestive heart failure No symptomatic coronary artery disease No clinically manifest hypotension No severe hypertension No arrhythmia electrocardiogram No edema No contraindication pressor agent Pulmonary : See Disease Characteristics No dyspnea rest severe exertional dyspnea Neurologic : No significant CNS dysfunction , include follow : Seizure disorder Active cerebrovascular disease Dementia delirium Other : No autoimmune disease , include psoriasis No uncontrolled peptic ulcer disease No uncontrolled infection No history adverse reaction interleukin2 HIV HTLVI negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior systemic topical chemotherapy ( 6 week since prior mitomycin nitrosoureas ) Endocrine therapy : At least 1 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy Surgery : No prior organ allograft At least 3 week since prior major surgery Other : At least 4 week since prior immunosuppressive therapy At least 2 week since prior phototherapy ( ultraviolet B [ UVB ] PUVA light therapy ) No concurrent phototherapy ( UVB PUVA light therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>